Similarly to SMARCD1, we found that numerous downstream targets of SMARCD2 (e.g., PTGR1, TRMP8, PGC) and SMARCD3 (e.g., EGF, PIK3AP1, HSD3B1) were AR-driven genes that are involved in prostate tumorigenesis, progression and metastasis [51,55,56,58,59,60]. This evidence concerns the gene AR and medical procedure.